Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Goldnboy1on Jun 25, 2023 9:59pm
364 Views
Post# 35513944

35% of float churned in 2 days!

35% of float churned in 2 days!

Extremely impressive volume. 35% of the float has changed hands in the past two days.

The average price traded Thursday Friday for all that volume is somewhere around $3.60.

Volume Monday is going to be huge. I have biotech funds circling this globally. Have in the past worked with some heavyweight players. Sent a few emails, hopefully they join the feeding frenzy!

This moment in history for the company just "feels different"!! Setting the stock up nicely for an even bigger announcement just before the long weekend!

If they don't want to announce fundraising for 90 days, stock could have a lot of market value left to fill in before that price is announced!

$30m on the balance sheet isn't enough for a stage 3 trial. Even with 50% off, you need a solid $50-$100m. No one in their right mind raises that kind of capital at $230m market cap. Have to think $800m - $1.2b the goal for that raise. Lots of comparables to back this math.

Get what you can and hang on tight!!

GLTA! 

<< Previous
Bullboard Posts
Next >>